|Public on Jul 30, 2014
|Prostate cancer specific gene expression
|Expression profiling by array
|To identify prostate cancer-specific gene expression, we have employed whole cDNA microarray expression profiling between benign prostate hypertrophy and prostate cancer. We performed needle biopsy of patients with prostatic hyperplasia who were suspected as prostate cancer for minor high level (4.0-10 ng/ml). As a result of needle biopsy, we used the tissue of patients with prostatic hyperplasia that prostate cancer was denied for cDNA microarry analysis. Furthermore, we also performed needle biopsy of patients that prostate cancer should have been strongly suspected because of high PSA.
Needle biopsies were performed after we obtained informed consent from patients with the document approved from the Graduate School of Medical Science, Kanazawa University.
|Gene expression profile was determied in each of normal prostate samples and prostate cancer samples. Then the profiles were compared between normal prostate samples and prostate cancer samples.
|Jul 27, 2011
|Last update date
|Feb 22, 2018
|School of Medicine
|Integrative Cancer Therapy and Urology
|Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Feature Number version)